Differential expression of DNA topoisomerase Ilo and -fl in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4
1996

Study of DNA Topoisomerase Expression in Drug-Resistant Lung Cancer Cells

publication Evidence: moderate

Author Information

Author(s): S WithofP, EGE de Vries, WN Keith, EF Nienhuis, WTA van der Graaf, DRA Uges, NH Mulder

Primary Institution: University Hospital Groningen

Hypothesis

The study investigates the role of DNA topoisomerase II isoforms in the resistance of small-cell lung carcinoma (SCLC) cell lines to topoisomerase-targeting drugs.

Conclusion

The study concludes that differential expression of topoisomerase II isoforms contributes to drug resistance in specific SCLC cell lines.

Supporting Evidence

  • GLC4/VM20 and GLC4/MIT60 showed decreased TopoIIa protein levels.
  • Resistance to drugs was correlated with decreased TopoIIa mRNA levels.
  • Drug accumulation defects were observed in resistant sublines.

Takeaway

Some cancer cells can become resistant to drugs because they change the way they use a special protein that helps fix their DNA. This study looks at how that happens in lung cancer cells.

Methodology

The study involved creating drug-resistant sublines of the GLC4 SCLC cell line and analyzing their topoisomerase expression, drug accumulation, and resistance factors.

Limitations

The study does not explore all potential resistance mechanisms beyond topoisomerase expression.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication